Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
76.72
+0.82 (+1.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
6,847,055
Open
76.09
Bid (Size)
76.00 (1)
Ask (Size)
76.98 (1)
Prev. Close
75.90
Today's Range
75.91 - 77.12
52wk Range
62.07 - 87.86
Shares Outstanding
1,253,809,440
Dividend Yield
3.91%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
August 22, 2024
Via
Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
August 21, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Performance
YTD
-7.83%
-7.83%
1 Month
+4.38%
+4.38%
3 Month
+16.81%
+16.81%
6 Month
+4.31%
+4.31%
1 Year
+0.51%
+0.51%
More News
Read More
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Peering Into Gilead Sciences's Recent Short Interest
August 20, 2024
Via
Benzinga
Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs
August 16, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
August 15, 2024
Via
Benzinga
Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat
August 08, 2024
Via
Investor's Business Daily
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
August 06, 2024
Via
Benzinga
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
August 15, 2024
Via
Benzinga
Exposures
Product Safety
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
August 14, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
7 Defensive Stocks to Buy as Investors Seek Shelter
August 14, 2024
Via
InvestorPlace
3 Stocks Retirees Should Absolutely Love
August 10, 2024
Via
The Motley Fool
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
August 09, 2024
Via
Benzinga
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
August 09, 2024
Via
Benzinga
Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript
August 08, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Gilead Sciences Announces Second Quarter 2024 Financial Results
August 08, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
August 08, 2024
Via
Benzinga
Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until...
August 08, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
Four Stocks To Watch This Week - Monday, August 5
August 05, 2024
Via
Talk Markets
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
August 03, 2024
Via
The Motley Fool
Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List
August 02, 2024
Via
InvestorPlace
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
August 02, 2024
Via
Benzinga
The Top 3 Biotech Stocks to Buy Now Summer 2024
July 31, 2024
Via
InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
July 31, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.